Human papillomavirus (HPV) infections play an important role in the pathogenesis of anogenital cancer and its precursors. HIV-infected individuals exhibit a high prevalence of HPV DNA. Several studies have further shown that HIV-infected individuals have an increased prevalence of squamous intraepithelial lesions (SIL) of the cervix, vulva and anus. The incidence of invasive cervical cancer is also elevated in HIV-positive women as well as that of anal cancer in HIV-positive women and men. Given the relationship between HIV-induced immunosuppression and HPV-associated disease, treatment with highly active antiretroviral therapy (HAART) has the potential, through immune reconstitution of the host, to alter the natural history of HPV infection and SIL. However, data on the impact of HAART on HPV disease are sparse and mixed results have been reported.
References
1.
KoutskyL., & KiviatN.Genital human papillomavirus. In: Sexually Transmitted Diseases, 1999. Edited by HolmesK.K., SparlingP.F., MardhP.A.. New York: McGraw-Hill.
2.
HoG., BiermanP., BeardsleyL., ChangC., & BurkR.Natural history of cervicovaginal papillomavirus infection in young women.New England Journal of Medicine1998; 338: 423–428.
3.
MuñozN., BoschF.X., deSanjoséS., TafurL., IzurgazaI., & ShahK.The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain.International Journal of Cancer1992; 52: 743–749.
4.
SchiffmanN.H., BauerH.M., HooverR.N., GlassA.G., CadellD.M., & ManosM.M.Epidemiologic evidence showing that human papilloma virus infection causes most cervical intraepithelial neoplasia.Journal of the National Cancer Institute1993; 85: 958–964.
5.
WalboomersJ.M.M., JacobsM.V., ManosM.M., BoschF.X., KummerJ.A., ShahK.V., SnijdersP.J.F., PetoJ., MeijerC.J.L.M., & MuñozN.Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.Journal of Pathology1999; 189: 12–19.
6.
FrischM., GlimeliusB., van den BruleA., WohlfahrtJ., MeijerC., WalboomersJ., GoldmanS., SvenssonC., AdamiH., & MelbyeM.Sexually transmitted infection as a cause of anal cancer.New England Journal of Medicine1997; 337: 1350–1358.
7.
GallowayD.Biology of genital human papillomaviruse. In: Sexually Transmitted Diseases, 1999. Edited by HolmesK.K., SparlingP.F., MardhP.A.. New York: McGraw-Hill.
8.
LorinczA., ReidR., JensonA., GreenbergM., LancasterW., & KurmanR.Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types.Obstetrics & Gynecology1992; 79: 328–337.
9.
MunozN., BoschF., & de SanjoseS.Epidemiologic classification of human papillomavirus types associated with cervical cancer.New England Journal of Medicine2003; 348: 518–527.
10.
International Agency for research on Cancer (IARC) Working Group on the Evaluation of Carcinogenic Risks to Humans.Human papillomaviruses. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol 64, 1995. Lyon, France: IARC.
11.
CliffordG., SmithJ., PlummerM., MunozN., & FranceschiS.Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis.British Journal of Cancer2003; 88: 63–73.
12.
BoschF.X., ManosM.M., MuñozN., ShermanM., JansenA.M., PetoJ., SchiffmanM.H., MorenoV., KurmanR., ShahK.V., & The International Biological Study on Cervical Cancer (I.B.S.C.C) Study Group. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective.Journal of the National Cancer Institute1995; 87: 796–802.
13.
SigstadE., LieA., LuostarinenT., DillnerJ., JellumE., LehtinenM., ThoresenS., & AbelerV.A prospective study of the relationship between prediagnostic human papillomavirus seropositivity and HPV DNA in subsequent cervical carcinomas.British Journal of Cancer2002; 87: 175–180.
14.
KjaerS., van den BruleA., PaullG., SvareE., ShermanM., ThomsenB., SuntumM., BockJ., PollP., & MeijerC.Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study.British Medical Journal2002; 325: 572–578.
15.
AlloubM., BarrB., & McLarenK.Human papillomavirus infection and cervical intraepithelial neoplasia in women with renal allografts.British Medical Journal1988; 298: 153–156.
16.
HalpertR., FruchterR.G., SedisA., ButtK., & SillmanF.H.Human papillomavirus and lower genital neoplasia in renal transplant patients.Obstetrics & Gynecology1986; 68: 251–258.
17.
SunX., KuhnL., EllerbrockT., ChiassonM-A, BushT., & WrightT.Human papillomavirus infection in women infected with the human immunodeficiency virus.New England Journal of Medicine1997; 337: 1343–1349.
18.
MassadL.S., RiesterK.A., AnastosK.M., FruchterR.G., PalefskyJ.M., & MiottiP.Prevalence and predictors of squamous cell abnormalities in Papanicolaou smears from women infected with HIV-1.Journal of Acquired Immune Deficiency Syndromes1999; 21: 33–41.
19.
PalefskyJ., HollyE., HogeboomC., RalstonM., DaCostaM., BottsR., BerryJ., JayN., & DarraghT.Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men.Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology1998; 17: 314–319.
20.
KingG., HealyC., GloverM., KwanJ., WilliamsD., LeighI., & ThornhillM.Prevalence and risk factors associated with leukoplakia, hairy leukoplakia, erythematous candidiasis, and gingival hyperplasia in renal transplant recipients.Oral Surgery, Oral Medicine & Oral Pathology1994; 78: 718–726.
21.
MocroftA., BrettleR., KirkO., BlaxhultA., ParkinJ., AntunesF., FrancioliP., D'Arminio MonforteA., FoxZ., & LundgrenJ.Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study.AIDS2002; 16: 1663–1671.
22.
PalellaF.J.Jr., DelaneyK.M., MoormanA.C., LovelessM.O., FuhrerJ., SattenG.A., AschmanD.J., & HolmbergS.D.Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.New England Journal of Medicine1998; 338: 853–860.
23.
DeaytonJ., MocroftA., WilsonP., EmeryV., JohnsonM., & GriffithsP.Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy.AIDS1999; 13: 1203–1206.
24.
NeytsJ., & De ClercqE.Antiviral drug susceptibility of human herpesvirus 8.Antimicrobial Agents & Chemotherapy1997; 41: 2754–2756.
25.
WittF., & RenwickN.Regression of AIDS-related Kaposi's sarcoma associated with clearance of human herpesvirus-8 from peripheral blood mononuclear cells following initiation of antiretroviral therapy.AIDS1998; 12: 218–219.
26.
JamiesonD.J., DuerrA., BurkR., KleinR.S., ParamsothyP., SchumanP., Cu-UvinS., & ShahK.Characterization of genital human papillomavirus infection in women who have or who are at risk of having HIV infection.American Journal of Obstetrics & Gynecology2002; 186: 21–27.
27.
SunX., EllerbrockT.V., LunguO., ChiassonM.A., BushT.J., & WrightT.C.Human papillomavirus infection in human immunodeficiency virus-seropositive women.Obstetrics & Gynecology1995; 85: 680–686.
28.
PalefskyJ., MinkoffH., KalishL., LevineA., SacksH., GarciaP., & BurkR.Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women.Journal of the National Cancer Institute1999; 91: 226–236.
29.
MinkoffH., FeldmanJ., De HovitzJ., LandesmanS., & BurkR.A longitudinal study of human papillomavirus carriage in human immunodeficiency virus-infected and human immunodeficiency virus-uninfected women.American Journal of Obstetrics & Gynecology1998; 178: 982–986.
30.
AhdiehL., KleinR.S., BurkR., Cu-UvinS., SchumanP., DuerrA., SafaeianM., AstemborskiJ., DanielR., & ShahK.Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women.Journal of Infectious Diseases2001; 184: 682–690.
31.
HeardI., TassieJ.M., SchmitzV., MandelbrotL., KazatchkineM.D., & OrthG.Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high papillomavirus load.Obstetrics & Gynecology2000; 96: 403–409.
32.
DuerrA., KiekeB., WarrenD., ShahK., BurkR., PeipertJ.F., SchumanP., & KleinR.S.Human papillomavirus-associated cervical cytologic abnormalities among women with or at risk of infection with human immunodeficiency virus.American Journal of Obstetrics & Gynecology2001; 184: 584–590.
33.
SixC., HeardI., BergeronC., OrthG., & De VincenziI.Comparative prevalence, incidence and short-term prognosis of cervical squamous intraepithelial lesions (SIL) among HIV(+) and HIV(–) women.AIDS1998; 12: 1047–1056.
34.
WrightT., EllerbrockT., ChiassonM., Van DevanterN., BrudneyK., & SunX.Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors, and validity of Papanicolaou smears.Obstetrics & Gynecology1994; 84: 591–597.
35.
MassadL.S., AhdiehL., BenningL., MinkoffH., GreenblattR.M., WattsH., MiottiP., AnastosK., MoxleyM., MuderspachL.I., & MelnickS.Evolution of cervical abnormalities among women with HIV-1: evidence from surveillance cytology in the women's interagency HIV study.Journal of Acquired Immune Deficiency Syndromes2001; 27: 432–442.
36.
PetryK.U., ScheffelD., BodeU., GabrysiakT., & SchedelI.Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions.International Journal of Cancer1994; 57: 836–840.
37.
PetryK., KochelH., & BodeU.Human papillomavirus is associated with the frequent detection of warty and basaloid high-grade neoplasia of the vulva and cervical neoplasia among immunocompromised women.Gynecologic Oncology1996; 60: 30–34.
38.
Centers for disease control and prevention.1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.Morbidity & Mortality Weekly Report1993; 41: 1–19.
RabkinC., BiggarR., BaptisteM., AbeT., & NascaP.Cancer incidence trends in women at high risk of human immunodeficiency virus (HIV) infection.International Journal of Cancer1993; 55: 208–212.
41.
FrischM., BiggarR.J., & GoedertJ.J.Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome.Journal of the National Cancer Institute2000; 92: 1500–1510.
42.
SilverbergM., AhdiehL., MunozA., AnastosK., BurkR., Cu-UvinS., DuerrA., GreenblattR., KleinR., MassadS., MinkoffH., MuderspachL., PalefskyJ., PiessensE., SchumanP., WattsH., & ShahK.The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts.Sexually Transmitted Diseases2002; 29: 427–435.
43.
ChirgwinK., FeldmanJ., AugenbraunM., LandesmanS., & MinkoffH.Incidence of venereal warts in human immunodeficiency virus-infected and uninfected women.Journal of Infectious Diseases1995; 172: 235–238.
44.
ChiassonM., EllerbrockT., BushT., SunX-W, & WrightT.Increased prevalence of vulvovaginal condyloma and vulvar intraepithelial neoplasia in women infected with the human immunodeficiency virus.Obstetrics & Gynecology1997; 89: 690–694.
45.
MinkoffH., Eisenberger-MatityahuD., FeldmanJ., BurkR., & ClarkeL.Prevalence and incidence of gynecologic disorders among women infected with human immunodeficiency virus.American Journal of Obstetrics & Gynecology1999; 180: 824–836.
HollyE.A., RalstonM., DarraghT., GreenblattR., JayN., & PalefskyJ.Prevalence and risk factors for anal squamous intraepithelial lesions in women.Journal of the National Cancer Institute2001; 93: 843–849.
48.
PalefskyJ.M., HollyE., & RalstonM.Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women.Journal of Infectious Diseases2001; 183: 383–391.
49.
KiviatN., CritchlowC., HolmesK., KuypersJ., SayerJ., DunphyC., SurawiczC., KirbyP., WoodR., & DalingJ.Association of anal dysplasia and human papillomavirus with immunosuppression and HIV infection among homosexual men.AIDS1993; 7: 43–49.
50.
PalefskyJ., HollyE., RalstonM., & JayN.Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men.Journal of Infectious Diseases1998; 177: 361–367.
51.
PalefskyJ., ShiboskiS., & MossA.Risk factors for anal human papillomavirus infection and anal cytologic abnormalities in HIV-positive and HIV-negative homosexual men.Journal of Acquired Immune Deficiency Syndromes1994; 7: 599–606.
52.
PalefskyJ., HollyE., RalstonM., JayN., BerryJ., & DarraghT.High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men.AIDS1998; 12: 495–503.
53.
PikettyC., DarraghT., Da CostaM., BrunevalP., HeardI., KazatchkineM., & PalefskyJ.High prevalence of anal squamous intraepithelial lesions and anal HPV infection in HIV-infected drug users.Annals of Internal Medicine2003; 138: 453–459.
54.
BouquotJ.Common oral lesions found during a mass screening examination.Journal of the American Dental Association1986; 112: 50–57.
55.
KingM., ReznikD., O'DanielsC., LarsenN., OsterholtD., & BlumbergH.Human papillomavirus-associated oral warts among human immunodeficiency virus-seropositive patients in the era of highly active antiretroviral therapy: an emerging infection.Clinical Infectious Diseases2002; 34: 641–648.
56.
GreenspanD., de VilliersE., GreenspanJ., De SouzaY., & zur HausenH.Unusual HPV types in oral warts in association with HIV infection.Journal of Oral Pathology1988; 17: 482–488.
57.
NuovoG., FordeA., MacConnellP., & FahrenwaldR.In situ detection of PCR-amplified HIV-1 nucleic acids and tumor necrosis factor cDNA in cervical tissues.American Journal of Pathology1993; 143: 40–48.
58.
NakagawaM., StitesD., FarhaT.S., JuddA., MoscickiA., CancholaA., HiltonJ., & PalefskyJ.T-cell proliferative response to human papillomavirus type 16 peptides: relationship to cervical intraepithelial neoplasia.Clinical Diagnosis & Laboratory Immunology1996; 3: 205–210.
59.
NakagawaM., StitesD., FarhatS., SislerJ., MossB., KongF., MoscickiA., & PalefskyJ.Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia.Journal of Infectious Diseases1997; 175: 927–931.
60.
SternP.Immunity to human papillomavirus-associated cervical neoplasia.Advances in Cancer Research1996; 69: 175–211.
61.
WangC., KreissJ., & ReillyM.Risk of HIV infection in oral contraceptive pill users: a meta-analysis.Journal of Acquired Immune Deficiency Syndromes1999; 21: 51–58.
62.
TagamiH., OguchiM., & OfujiS.The phenomenon of spontaneous regression of numerous flat warts: immunohistological studies.Cancer1980; 45: 2557–2563.
63.
ColemanN., BirleyH., RentonA., HannaN., RyaitB., ByrneM., Taylor-RobinsonD., & StanleyM.Immunological events in regressing genital warts.American Journal of Clinical Pathology1994; 102: 768–774.
64.
BontkesH., de GruijlT., van den MuysenbergA., VerheijenR., StukarM., MeijerC., ScheperR., StaceyS., Duggan-KeenM., SternP., ManS., BorysiewiczL., & WalboomersJ.Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia.International Journal of Cancer2000; 88: 92–98.
65.
MalejczykJ., MalejczyK.M., KöckA., UrbanskiA., MajewskiS., & HunzelmannN.Autocrine growth limitation of human papillomavirus type 16-harboring keratinocytes by constitutively released tumor necrosis factor-alpha.Journal of Immunology1992; 149: 2702–2708.
66.
RöslF., Kleine-LowinskiK., & zur HausenH.The possible role of chemokines in HPV-linked carcinogenesis. In: Chemokines and Cancer, 1999; pp. 207–225. Edited by RollinsB.J.Totowa: Humana Press, Inc.
67.
AranyI., & TyringS.Systemic immunosuppression by HIV infection influences HPV transcription and thus local immune responses in condyloma acuminatum.International Journal of Sexually Transmitted Diseases & AIDS1998; 9: 268–271.
68.
VernonS., HartC., ReevesW., & IcenogleJ.The HIV-1 tat protein enhances E2-dependent human papillomavirus 16 transcription.Virus Research1993; 27: 133–145.
69.
CarcelainG., DebreP., & AutranB.Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following anti-retroviral therapy.Current Opinion on Immunology2001; 13: 483–488.
70.
LiT., TubianaR., KatlamaC., CalvezV., Ait MohandH., & AutranB.Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease.Lancet1998; 351: 1682–1686.
71.
TillM., HelenowskiI., RademakerA., & LandayA.Changes in cytokine levels in the genital tract of women infected with human immunodeficiency virus type-1 (HIV) during treatment with highly active antiretroviral therapy.14th International Conference on AIDS. Barcelona, Spain, 7–12 July 2002.
72.
PalefskyJ., HollyE., RalstonM., Da CostaM., BonnerH., JayN., BerryJ., & DarraghT.Effect of highly active anti-retroviral therapy on the natural history of anal squamous intraepithelial lesions and anal human papillomavirus infection.Journal of Acquired Immune Deficiency Syndromes2001; 28: 422–428.
73.
HeardI., SchmitzV., CostagliolaD., OrthG., & KazatchkineM.Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy.AIDS1998; 12: 1459–1464.
74.
LilloF., FerrariD., VegliaF., & Uberti-FoppaC.human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy.Journal of Infectious Diseases2001; 184: 547–551.
75.
ConleyL., EllerbrockT.V., BushT.J., ChiassonM.A., SawoD., & WrightT.C.HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study.Lancet2002; 359: 108–113.
76.
PikettyC., DarraghT., HeardI., Da CostaM., BrunevalP., KazatchkineM.D., & PalefskyJ.High prevalence of anal squamous intraepithelial lesions in HIV-positive men despite use of highly active antiretroviral therapy.Sexually Transmitted Diseases. In Press.
77.
WilkinT., PalmerS., BrudneyK., ChiassonM.A., & WrightT.The association of antiretroviral therapy with anal squamous intraepithelial lesions among HIV positive men.10th Conference on Retroviruses & Opportunistic Infections. Boston, Mass., USA, 10–14 February 2003. Abstract 819.
78.
MinkoffH., AhdiehL., MassadL.S., AnastosK., WattsD.H., MelnickS., MuderspachL., BurkR., & PalefskyJ.The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women.AIDS2001; 15: 2157–2164.
79.
HeardI., TassiéJ., KazatchkineM., & OrthG.Increased regression of CIN in HIV-seropositive women under HAART.AIDS2002; 16: 1799–1802.
80.
LuqueA., LiH., DemeterL., & ReichmanR.Effect of anti-retroviral therapy (ARVT) on human papillomavirus (HPV) infection and disease among HIV-infected women.8th Conference on Retroviruses & Opportunistic Infections. Chicago, Ill., USA, 4–8 February 2001. Abstract 724.
81.
KhannaN., TaylorG., LangenbergP., & FurthP.HAART and its influence on HPV related cervical disease in women with HIV.5th International AIDS Malignancy Conference. 2001.
82.
OrlandoG., FasoloM.M., SchiaviniM., SignoriR., & CargnelA.Role of highly active antiretroviral therapy in human papillomavirus-induced genital dysplasia in HIV-1 infected patients.AIDS1999; 13: 424–425.
83.
Del MistroA., FranzettiM., & CattelanA.Clinical and virological features of HPV-associated genital lesions in HIV-infected women.3rd International Conference on Malignancies in AIDS & Other Immunodeficiencies. Bethesda, Md., USA, 1999. Abstract 11.
84.
MooreA., SabinC., MadgeS., MocroftA., ReidW., & JohnsonM.Highly active antiretroviral therapy and cervical intraepithelial neoplasia.AIDS2002; 16: 927–929.
85.
KovacsA., WassermanS., BurnsD., WrightD., CohnJ., LandayA., WeberK., CohenM., LevineA., MinkoffH., MiottiP., PalefskyJ., YoungM., & ReichelderferP.Determinants of HIV-1 shedding in the genital tract of women.Lancet2001; 358: 1593–1601.
86.
HartC., LennoxJ., Pratt-PalmoreM., WrightT., SchinaziR., Evans-StrickfadenT., BushT., SchnellC., ConleyL., ClancyK., & EllerbrockT.Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract.Journal of Infectious Diseases1999; 179: 871–882.
87.
RobinsonW.R., HamiltonC.A., MichaelsS.H., & KissingerP.Effect of excisional therapy and highly active antiretroviral therapy on cervical intraepithelial neoplasia in women infected with human immunodeficiency virus.American Journal of Obstetrics & Gynecology2001; 184: 538–543.
88.
KellerJ., SewellC., TrimbleC., & LeeJ.Correlates of recurrent cervical dysplasia in HIV positive women after excisional treatment.14th International Conference on AIDS. Barcelona, Spain, 7–12 July 2002.
89.
WrightT., BushT., SawoD., ConleyL., WuF., & EllerbrockT.A clinical trial comparing standard treatment modalities for squamous intraepithelial lesions of the cervix in HIV-infected women.9th Conference on Retroviruses & Opportunistic Infections. Seattle, Wash., USA, 24–28 February 2002. Abstract LB 16.
90.
International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults.Journal of the National Cancer Institute2000; 92: 1823–1830.
91.
USPHS/IDSA Prevention of Opportunistic Infection Working Group.1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus.Annals of Internal Medicine1997; 127: 923–946.
92.
PalefskyJ., HollyE.A., & RalstonM.Effect of HAART on incidence of anal intraepithelial neoplasia grade 3 among HIV-positive men who have sex with men.14th International Conference on AIDS. Barcelona, Spain, 7–12 July 2002.
93.
PalefskyJ., HollyE., TalstonM., JayN., BerryJ., & DarraghT.Effect of HAART on prevalence of anal intraepithelial neoplasia 2 and 3.6th International Conference on Malignancies in AIDS & Other Immunodeficiencies. Bethesda, Md., USA, 22–24 April 2002. Abstract 2.
94.
KiviatN., RedmanM., HawesS., LampinenT., NelsonP., & CritcholowC.The effect of HAART on detection of anal HPV and squamous intraepithelial lesions among HIV infected homosexual men.6th International Conference on Malignancies in AIDS & Other Immunodeficiencies. Bethesda, Md., USA, 22–24 April 2002. Abstract 1.
95.
GallowayD., & McDougallJ.The disruption of cell cycle checkpoints by papillomavirus oncoproteins contributes to anogenital neoplasia.Seminars in Cancer Biology1996; 7: 309–315.
96.
PalefskyJ.Anal squamous intraepithelial lesions in human immunodeficiency virus-positive men and women.Seminars in Oncology2000; 27: 471–479.
97.
GreenspanD., CancholaA., MacPhailL., CheikhB., & GreenspanJ.Effect of highly active antiretroviral therapy on frequency of oral warts.Lancet2001; 357: 1411–1412.
98.
MastroianniC., TrinchieriV., SantopadreP., LichtnerM., ForcinaG., D'AgostinoC., CorpolongoA., & VulloV.Acute clinical hepatitis in an HIV-seropositive hepatitis B carrier receiving protease inhibitor therapy.AIDS1998; 12: 1939–1940.
99.
KreiderJ., HowettM., StolerM., ZainoR., & WelshP.Susceptibility of various human tissues to transformation in vivo with human papillomavirus type 11.International Journal of Cancer1987; 39: 459–465.
100.
GlesbyM., & HooverD.Survivor treatment selection bias in observational studies: examples from the AIDS literature.Annals of Internal Medicine1996; 124: 999–1005.
